Clinical Trials List
2012-08-01 - 2018-10-25
Phase III
Study ended4
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/19
Investigators and Locations
Co-Principal Investigator
- Jih-Luh Tang Division of Hematology & Oncology
- 林建廷 Division of Hematology & Oncology
- HSIN-AN HOU Division of Hematology & Oncology
- 徐思淳 Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- Shang-Yi Huang Division of Hematology & Oncology
- Wen-Chien Chou Division of Hematology & Oncology
- 李啟誠 Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- Jyh-Pyng Gau Division of Hematology & Oncology
- 洪英中 Division of Hematology & Oncology
- 余垣斌 Division of Hematology & Oncology
- Liang-Tsai Hsiao Division of Hematology & Oncology
- Chun-Yu Liu Division of Hematology & Oncology
- Jin-Hwang Liu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- 楊陽生 Division of Hematology & Oncology
- Chieh-Lin Teng Division of Hematology & Oncology
- Huey-En Tzeng Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Study ended
The Actual Total Number of Participants Enrolled
0 Study ended
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
292 participants
